Title of article :
Comparison of Two brands of Methylphenidate (Stimdate® vs. Ritalin®) in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial
Author/Authors :
Khodadust، Naser نويسنده Psychiatrist, Mental Health Research Center, Tehran Psychiatric Institute, Tehran University of Medical Sciences and Health Services, Tehran, Iran , , Jalali، Amir-Hossein نويسنده Assistant Professor of Psychiatry, Mental Health Research Center, Tehran Psychiatric Institute, Tehran University of Medical Sciences and Health Services, Tehran, Iran. , , Ahmadzad Asl، Masoud نويسنده Department of Psychiatry, Qazvin University of Medical Sciences, Qazvin, IR Iran Ahmadzad Asl, Masoud , Khademolreza، Noushin نويسنده Psychiatrist, Mental Health Research Center, Tehran Psychiatric Institute, Tehran University of Medical Sciences and Health Services, Tehran, Iran. , , Shirazi، Elham نويسنده Department of Pediatric Psychology, Research Center of Pediatric Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran Shirazi, Elham
Issue Information :
فصلنامه با شماره پیاپی 0 سال 2012
Pages :
7
From page :
26
To page :
32
Abstract :
Objective: To compare the effectiveness and safety of the methylphenidate produced in Iran (Stimdate®) with its original brand (Ritalin®) in children with Attention deficit hyperactivity disorder (ADHD). Methods: In this double-blinded randomized clinical trial, 30 patients with ADHD who were 6 to 16 years old, were divided into two groups: 15 in Stimdate® and 15 in Ritalin® group. The two groups were compared for side effects profile, Conner?s Parent?s Rating Scale-Persion version (CPRS-R), Child Symptom Inventory-4 (CSI-4), Clinical Global Impressions (CGI), and Children?s Global Assessment Scale (CGAS), at baseline and at the 4th and 6th weeks. Results: The subjects showed significant decreases in the CPRS-Rand CSI-4 scores and significant increase of CGAS scores during the follow-up, but there were no significant difference between Stimdate® and Ritalin® group, regarding the pattern of changes observed. The mean therapeutic dose and the number of side effects were not significantly different between the two studied groups. Conclusions: Both Stimdate® and Ritalin® had comparable clinical efficacy and safety in children with ADHD. Declaration of interest: None. Clinical Trial Registration-URL: http:// #_ > www.irct.ir. Unique identifier: IRCT201106306923N1. Citation: Comparison of two brands of methylphenidate (Stimdate® vs. Ritalin®) in children and adolescents with attention deficit hyperactivity disorder: a double-blind, randomized clinical trial. Khodadust N.Jalali AH, Ahmadzad-Asl M, Khademol N, Shirazi E .Iran J Psychiatry Behave Sci 2012; 6(1): 26-32.
Journal title :
Iranian Journal of Psychiatry and Behavioral Sciences (IJPBS)
Serial Year :
2012
Journal title :
Iranian Journal of Psychiatry and Behavioral Sciences (IJPBS)
Record number :
2385046
Link To Document :
بازگشت